Search results for "Prostatic neoplasm"

showing 10 items of 285 documents

Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.

2017

Objective To evaluate the impact of preoperative risk category on metastatic disease and prostate cancer-specific mortality (CSM) in patients with prostate cancer (PCa) with adverse pathology at radical prostatectomy (RP). Patients and Methods The records of 6 943 patients who underwent RP at a European tertiary centre were analysed. Biochemical recurrence (BCR), metastatic disease and CSM were assessed for patients with adverse pathology at RP, and stratified according to preoperative low- vs intermediate-/high-risk PCa groups. Kaplan–Meier, cumulative incidence, Cox regression and competing risk regression analyses were performed. Results In patients with extracapsular extension, the meta…

Biochemical recurrenceMalemedicine.medical_specialtyPathologyUrologymedicine.medical_treatment030232 urology & nephrologyUrologyKaplan-Meier EstimateLower riskCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineRisk FactorsMedicineHumansCumulative incidencePathologicalAgedProstatectomybusiness.industryProportional hazards modelProstatectomyHazard ratioProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.disease030220 oncology & carcinogenesisMultivariate AnalysisbusinessBJU international
researchProduct

10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.

2020

Purpose The primary aim of this multicenter retrospective analysis is to examine the role of(18)F-choline PET/CT as a diagnostic tool for staging and restaging prostate cancer (PCa) in a large population in the light of 10 years of clinical experience. A secondary aim of the study is to produce data on the predictors of a positive(18)F-choline PET/CT result in the setting of PCa primaries and biochemical recurrences. Materials and Methods This multicenter retrospective cohort study is based on data collected by 9 Italian nuclear medicine departments. Between October 2008 and September 2019, 3343 men underwent(18)F-choline PET/CT scans before receiving definitive treatments for a primary PCa…

Biochemical recurrenceMalemedicine.medical_specialtyProstate biopsyrecurrencePET/CTcholine; PET/CT; prostate cancer; recurrence; staging030218 nuclear medicine & medical imagingCholine03 medical and health sciencesProstate cancer0302 clinical medicineSettore MED/36ProstatePositron Emission Tomography Computed Tomography80 and overMedicineHumansRadiology Nuclear Medicine and imagingTomographyCancer stagingAgedAged 80 and overPET-CTmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsRetrospective cohort studyGeneral MedicinestagingMiddle Agedmedicine.diseaseprostate cancerX-Ray ComputedProstate-specific antigenmedicine.anatomical_structurePET030220 oncology & carcinogenesisRadiologyNeoplasm GradingRadiopharmaceuticalsbusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedCT; choline; prostate cancer; recurrence; staging; Aged; Aged 80 and over; Choline; Humans; Male; Middle Aged; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography X-Ray ComputedCTClinical nuclear medicine
researchProduct

Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.

2007

Abstract The clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM). Cathepsin K and cystatin C circulating levels were determined by ELISAs in 63 cancer patients, in 35 patients with nonmalignant diseases and in 42 healthy blood donors (control group). In BCa patients, cathepsin K serum levels were significantly lower than in sex matched control group (HS; p  = 0.0008) or in patients with primary osteoporosis (OP; p  = 0.0009). On the contrary, cystatin C levels were significantly higher in BCa patients than in HS ( p  = 0.0001) or OP ( p  = 0.017). In PCa patien…

CA15-3Malemedicine.medical_specialtyCathepsin KProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesZoledronic AcidProstate cancerInternal medicinemedicineCathepsin KBiomarkers TumorHumansCystatin CAgedPharmacologyAged 80 and overbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryBone cancerImidazolesCancerBone metastasisProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsCystatinsBone metastasis; cathepsin K; Cystatin CEndocrinologyZoledronic acidCystatin CROC CurveBone metastasiCase-Control Studiesbiology.proteinDisease ProgressionOsteoporosisFemaleDrug Monitoringbusinessmedicine.drugBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Accelerated T2-Weighted TSE Imaging of the Prostate Using Deep Learning Image Reconstruction: A Prospective Comparison with Standard T2-Weighted TSE …

2021

Multiparametric MRI (mpMRI) of the prostate has become the standard of care in prostate cancer evaluation. Recently, deep learning image reconstruction (DLR) methods have been introduced with promising results regarding scan acceleration. Therefore, the aim of this study was to investigate the impact of deep learning image reconstruction (DLR) in a shortened acquisition process of T2-weighted TSE imaging, regarding the image quality and diagnostic confidence, as well as PI-RADS and T2 scoring, as compared to standard T2 TSE imaging. Sixty patients undergoing 3T mpMRI for the evaluation of prostate cancer were prospectively enrolled in this institutional review board-approved study between O…

Cancer Researchdiagnostic imagingImage qualityIterative reconstructionArticleprostatic neoplasms030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstateMedical imagingmedicineRC254-282Multiparametric Magnetic Resonance Imagingbusiness.industryDeep learningNeoplasms. Tumors. Oncology. Including cancer and carcinogensdeep learningmultiparametric magnetic resonance imagingmedicine.diseasemedicine.anatomical_structureOncology030220 oncology & carcinogenesisArtificial intelligenceNuclear medicinebusinessT2 weightedCancers
researchProduct

Direct determination of intracellular daunorubicin in intact confluent monolayers of AT1 prostate carcinoma cells using a multiwell–multilabel counter

2008

The cytostatic drug daunorubicin exerts its toxic action by intercalating into the DNA. The efficacy of daunorubicin depends on the intracellular amount in the tumor cell. Here we have evaluated the use of a multiwell-multilabel reader for the direct determination of the fluorescent cytostatic drug daunorubicin in a prostate carcinoma cell line (AT1 R-3327 Dunning prostate carcinoma cells) grown on 24-well plates. We present evidence that this simple fluorescent parameter is a good measure for the toxicologically relevant amount of the drug intercalated into the DNA and, therefore, is a good predictor for the drug's cytotoxicity. The amount of cationic cytostatics in a tumor cell is primari…

Cell ExtractsMaleDrugTime FactorsDaunorubicinmedia_common.quotation_subjectIntracellular SpaceBiophysicsBiochemistryChemistry Techniques AnalyticalCell Line Tumorpolycyclic compoundsmedicineAnimalsATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityMolecular BiologyCell ProliferationP-glycoproteinmedia_commonbiologyDaunorubicinProstatic NeoplasmsDNA NeoplasmCell BiologyRatsMultiple drug resistanceSpectrometry FluorescenceVerapamilBiochemistryCell cultureCancer researchbiology.proteinEffluxIntracellularSubcellular Fractionsmedicine.drugAnalytical Biochemistry
researchProduct

Alkylresorcinol Metabolites in Urine and Plasma as Potential Biomarkers of Rye and Wheat Fiber Consumption in Prostate Cancer Patients and Controls

2015

Alkylresorcinols (ARs) are phytochemicals mainly associated with rye/wheat bran. Plasma ARs and their plasma and urine metabolites are considered as biomarkers for whole-grain rye/wheat intake. However ARs metabolite day and night variations have not been studied in prostate cancer patients yet. We investigated ARs metabolites 3, 5-dihydroxy-benzoic acid (DHBA), and 3-(3, 5-dihydroxyphenyl)-1-propanoic acid (DHPPA) in urine and plasma in prostate cancer patients and in control group. DHPPA in 12-h overnight urine correlated with the intake of rye bread and bread fiber across short time periods (3 days). Plasma DHPPA concentration was significantly greater in the prostate cancer group than i…

Dietary FiberMaleCancer Researchmedicine.medical_specialty030309 nutrition & dieteticsMetaboliteMedicine (miscellaneous)030209 endocrinology & metabolismUrineExcretion03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineAlkylresorcinolInternal medicineHydroxybenzoatesmedicineHumansTriticumAged0303 health sciencesNutrition and DieteticsPhenylpropionatesBranSecaledigestive oral and skin physiologyCase-control studyProstatic Neoplasmsfood and beveragesBreadResorcinolsMiddle Agedmedicine.disease6. Clean waterCircadian Rhythm3. Good healthEndocrinologyOncologychemistryBiochemistryCase-Control StudiesPotential biomarkersBiomarkersNutrition and Cancer
researchProduct

From In Silico to Experimental Validation: Tailoring Peptide Substrates for a Serine Protease.

2020

Smart nanocarriers for the transport of drugs to tumor cells are nowadays of great interest for treating cancer. The use of enzymatic stimuli to cleave peptide-based drug nanocapsules for the selective release of nanocapsule cargo in close proximity to tumor cells opens new possibilities in cancer research. In the present work, we demonstrate a methodology for finding and optimizing cleavable substrate sequences by the type II transmembrane serine protease hepsin, which is highly overexpressed in prostate cancer. The design and screening of combinatorial libraries in silico against the binding cavity of hepsin allow the identification of a panel of promising substrates with high-calculated …

DrugMalePolymers and PlasticsIn silicoHepsinmedia_common.quotation_subjectBioengineeringPeptide02 engineering and technology010402 general chemistry01 natural sciencesNanocapsulesBiomaterialsCleaveCell Line TumorMaterials ChemistryHumansComputer Simulationmedia_commonSerine proteasechemistry.chemical_classificationbiologyChemistryProstatic Neoplasms021001 nanoscience & nanotechnology0104 chemical sciencesBiochemistrybiology.proteinNanocarriersSerine Proteases0210 nano-technologyPeptidesBiomacromolecules
researchProduct

(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors

2015

Purpose The present study aims at developing and evaluating an urea-based prostate specific membrane antigen (PSMA) inhibitor suitable for labeling with 111In for SPECT and intraoperative applications as well as 68Ga and 64Cu for PET imaging. Methods The PSMA-based inhibitor-lysine-urea-glutamate-coupled to the spacer Phe-Phe-D-Lys(suberoyl) and functionalized with the enantiomerically pure prochelator (R)-1-(1-carboxy-3-carbotertbutoxypropyl)-4,7-carbotartbutoxymethyl)-1,4,7-triazacyclononane ((R)-NODAGA(tBu)3), to obtain (R)-NODAGA-Phe-Phe-D-Lys(suberoyl)-Lys-urea-Glu (CC34). CC34 was labeled with 111In, 68Ga and 64Cu. The radioconjugates were further evaluated in vitro and in vivo in LNC…

Glutamate Carboxypeptidase IIMaleBiodistributionPathologymedicine.medical_specialtylcsh:MedicineGallium RadioisotopesAcetatesurologic and male genital diseasesHeterocyclic Compounds 1-RingMicechemistry.chemical_compoundPharmacokineticsIn vivoLNCaPImage Processing Computer-AssistedTumor Cells CulturedGlutamate carboxypeptidase IImedicineAnimalsHumansTissue Distributionlcsh:ScienceIncubationMice Inbred BALB CMultidisciplinaryChemistrylcsh:RProstatic NeoplasmsXenograft Model Antitumor AssaysMolecular biologyIn vitroPositron-Emission TomographyAntigens SurfaceUreaFemalelcsh:QRadiopharmaceuticalsResearch ArticlePLOS ONE
researchProduct

Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter It…

2011

Objective. A number of evidence-based guidelines for diagnosis and management of prostate cancer have been published. The aim of this study is to evaluate the adherence of Italian urologists to the guidelines concerning the preoperative imaging staging of prostate cancer.Methods. In October 2007 a multicentric observational perspective study called Multicentric Italian Report on Radical prostatectomy Outcome and Research (MIRROR) was started in 135 Italian urology centers. Recruitment was closed in December 2008 and 2,408 cases were collected. In this paper we have taken into consideration all examinations carried out for preoperative imaging staging, evaluating compliance with the recommen…

Gynecologymedicine.medical_specialtyArticle Subjectbusiness.industryProstatectomyUrologyGeneral surgerymedicine.medical_treatmentObstetrics and Gynecologylcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923Gleason grademedicine.diseaseManagement of prostate cancerProstate cancerPreoperative stagingClinical StudyMedicineObservational studyProstatic Neoplasms Bone and Bones scan indexbusinessCost of carePreoperative imagingAdvances in urology
researchProduct

Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study.

2019

Objective: To report preliminary findings of a phase II study exploring the clinical outcomes of moderate hypofractionated radiotherapy performed with helical tomotherapy (HT) using computed tomography–magnetic resonance imaging–based planning for localized prostate cancer. Methods: The phase II prospective study received ethics approval from our institutional ethics committee. A dose of 60 Gy/20 fractions for low–intermediate risk prostate cancer by means of HT was explored. Primary endpoints of the study were acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. Secondary endpoints were quality of life and biochemical-free survival. Results: A total of 35 patients were i…

Hypofractionated RadiotherapyMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmenttomotherapyPhases of clinical researchTomotherapy030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicinePreliminary reportProstatemedicineBiomarkers TumorHumansProspective StudiesNeoplasm MetastasisProspective cohort studyRadiometryProstate hypofractionation tomotherapyAgedNeoplasm StagingAged 80 and overhypofractionationbusiness.industryRadiotherapy Planning Computer-AssistedProstateProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasehypofractionation; Prostate; tomotherapymedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisQuality of LifeObservational studyRadiation Dose HypofractionationRadiologyRadiotherapy Intensity-ModulatedbusinessFollow-Up StudiesTumori
researchProduct